In Japan, DAVtherapy (DTIC in combination with nimustine hydrochloride (ACNU) and vincristine (VCR)) has been used in the adjuvant setting for advanced melanoma for the last 30 years, although no clinical trial was conducted for DAV therapy with or without IFN-β [13,14]. The gene discussed is IFNB1; the disease is melanoma.